This HTML5 document contains 42 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB02329/identifier/chemspider/
n12http://bio2rdf.org/drugbank:
admshttp://www.w3.org/ns/adms#
n9http://linked.opendata.cz/resource/drugbank/drug/DB02329/identifier/wikipedia/
n11http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n7http://linked.opendata.cz/resource/drugbank/drug/DB02329/identifier/pdb/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n8http://linked.opendata.cz/resource/drugbank/drug/DB02329/identifier/pubchem-compound/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://linked.opendata.cz/resource/drugbank/drug/DB02329/identifier/pubchem-substance/
n15http://linked.opendata.cz/resource/drugbank/drug/DB02329/identifier/drugbank/

Statements

Subject Item
n2:DB02329
rdf:type
n3:Drug
n3:description
An agent derived from licorice root. It is used for the treatment of digestive tract ulcers, especially in the stomach. Antidiuretic side effects are frequent, but otherwise the drug is low in toxicity. [PubChem]
n3:generalReferences
# Sandeep TC, Yau JL, MacLullich AM, Noble J, Deary IJ, Walker BR, Seckl JR: 11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics. Proc Natl Acad Sci U S A. 2004 Apr 27;101(17):6734-9. Epub 2004 Apr 7. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/15071189
n3:group
experimental
owl:sameAs
n11:DB02329 n12:DB02329
dcterms:title
Carbenoxolone
adms:identifier
n6:46508820 n7:CBO n8:46936354 n9:Carbenoxolone n14:2463 n15:DB02329
n3:synthesisReference
Gottfried, S. and Baxendale, L.; U.S. Patent 3,070,623; December 25,1962; assigned to Biorex Laboratories Limited, England.
n3:IUPAC-Name
n4:271B535C-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5362-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5361-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B535E-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B535F-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5360-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B535A-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5358-363D-11E5-9242-09173F13E4C5 n4:271B535B-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5359-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B5368-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5369-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5363-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5364-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5366-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5365-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5367-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
5697-56-3
n3:Bioavailability
n4:271B536E-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5370-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5371-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5372-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B536D-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B536C-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B536F-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B535D-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B536A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B536B-363D-11E5-9242-09173F13E4C5